Connect Biopharma Holdings Ltd
NASDAQ:CNTB

Watchlist Manager
Connect Biopharma Holdings Ltd Logo
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
Watchlist
Price: 2.4 USD -5.51% Market Closed
Market Cap: 134.2m USD

Wall Street
Price Targets

CNTB Price Targets Summary
Connect Biopharma Holdings Ltd

Wall Street analysts forecast CNTB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for CNTB is 8.06 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.

Lowest
Price Target
6.06 USD
153% Upside
Average
Price Target
8.06 USD
236% Upside
Highest
Price Target
10.5 USD
338% Upside
Connect Biopharma Holdings Ltd Competitors:
Price Targets
2126
JW (Cayman) Therapeutics Co Ltd
100% Upside
KURN
Kuros Biosciences AG
15% Upside
4587
PeptiDream Inc
125% Upside
PHIL
Philogen SpA
13% Upside
KALV
Kalvista Pharmaceuticals Inc
92% Upside
TIL
Instil Bio Inc
794% Upside
NVAX
Novavax Inc
87% Upside
300685
Amoy Diagnostics Co Ltd
32% Upside

Revenue
Forecast

Revenue Estimate
Connect Biopharma Holdings Ltd

The compound annual growth rate of Connect Biopharma Holdings Ltd's revenue for the next 3 years is 70%.

N/A
Past Growth
70%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Connect Biopharma Holdings Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-43%
Average Miss

Net Income
Forecast

Net Income Estimate
Connect Biopharma Holdings Ltd

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-44%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CNTB's stock price target?
Price Target
8.06 USD

According to Wall Street analysts, the average 1-year price target for CNTB is 8.06 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.

What is Connect Biopharma Holdings Ltd's Revenue forecast?
Projected CAGR
70%

The compound annual growth rate of Connect Biopharma Holdings Ltd's revenue for the next 3 years is 70%.

Back to Top